Flagyl ( DrugBank: - )

2 diseases

ID	Disease name (Link within this page)	Number of trials
96	Crohn disease	2
97	Ulcerative colitis	2

96. Crohn disease

Clinical trials : 2,442 / Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04682522 (ClinicalTrials.gov)	March 21, 2021	9/12/2020	Flagyl Microbiome in Crohn's Disease	Does the Microbiome Change With Flagyl Treatment After Ileocolic Resection for Crohn's Disease	Crohn Disease	Drug: Metronidazole Oral	University of Louisville	NULL	Recruiting	20 Years	80 Years	All	36	Phase 4	United States
2	EUCTR2011-000885-36-ES (EUCTR)	26/12/2011	29/11/2011	Adalimub treatment to prevent recurrency post-surgery in Crohn disease.	Multicentric, randomized double blind clinical trial and paralell groups to compare Adalimub vs Azatioprina efficacy prevention in Crhon disease post-surgical recurrency after 52 weeks of treatment - APPRECIA	Compare efficay of Adalimub vs Azatioprina to prevent surgical intervention in Chron disease;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: Humira Product Name: Humira INN or Proposed INN: Adalimumab Other descriptive name: Adalimumab Trade Name: Imurel Product Name: Imurel INN or Proposed INN: Azatioprina Other descriptive name: Imurel Trade Name: Flagyl Product Name: Flagyl INN or Proposed INN: Metronidazol Other descriptive name: Flagyl	GETECCU	NULL	Not Recruiting			Female: yes Male: yes			Spain

97. Ulcerative colitis

Clinical trials : 2,630 / Drugs : 1,459 - (DrugBank : 265) / Drug target genes : 144 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000009811	2013/01/23	21/01/2013	Comparison of randomized trials of antibiotic combination therapies for patients with ulcerative colitis	Comparison of randomized trials of antibiotic combination therapies for patients with ulcerative colitis - Antibiotics trials for ulcerative colitis	Ulcerative colitis	One group is to receive two-week combination therapy consisting of amoxicillin (Sawacillin) 500 mg t.i.d, tetracycline (Acromycin) 500 mg t.i.d, and metronidazole (Flagyl) 250 mg t.i.d. with an inhibitor of gastric acid secretion. Patients are to be followed for 3 months (first endpoint). Another group will receive two week combination therapy consisting of amoxicillin (Sawacillin) 500 mg t.i.d, fosfomycin (Fosmicin) 1000mg t.i.d, and metrozole (Flagyl) 250 mg t.i.d, with an inhibitor of gastric acid secretion. Patients are to be followed for 3 months.	Division of General Medicine, Department of Internal Medicine, Nihon University School of Medicine	NULL	Complete: follow-up complete	16years-old	75years-old	Male and Female	40	Phase 3	Japan
2	EUCTR2009-015136-14-BE (EUCTR)	20/11/2009	12/10/2009	Modified release metronidazole for the treatment of pouchitis after colectomy with ileo-anal pouch anastomosis for ulcerative colitis: a pharmacokinetic study	Modified release metronidazole for the treatment of pouchitis after colectomy with ileo-anal pouch anastomosis for ulcerative colitis: a pharmacokinetic study	Pouchitis MedDRA version: 12.0;Level: LLT;Classification code 10036463;Term: Pouchitis	Product Name: Metronidazole capsule 50 mg Product Code: FP-110 INN or Proposed INN: Metronidazole Trade Name: Flagyl INN or Proposed INN: Metronidazole	FORMAC Pharmaceuticals NV	NULL	Not Recruiting			Female: yes Male: yes			Belgium